Ryan Deschner
Stock Analyst at Raymond James
(1.74)
# 1131
Out of 5,326 analysts
10
Total ratings
50.00%
Success rate
28.44%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
INZY Inozyme Pharma | Maintains: Outperform | 24 12 | 0.96 | 1150% | 1 | Mar 12, 2025 | |
TRVI Trevi Therapeutics | Upgrades: Strong Buy | 9 29 | 6.35 | 356.69% | 2 | Mar 10, 2025 | |
ARDX Ardelyx | Reiterates: Strong Buy | 15 13 | 5.03 | 158.45% | 1 | Feb 21, 2025 | |
SPRY ARS Pharmaceuticals | Maintains: Strong Buy | 26 28 | 14.63 | 91.39% | 3 | Jan 14, 2025 | |
LQDA Liquidia | Upgrades: Strong Buy | 27 27 | 14.03 | 92.44% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 12 | n/a | n/a | 1 | Jun 18, 2024 |